

Elizabeth M Swisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8296988/publications.pdf>

Version: 2024-02-01

129
papers

14,102
citations

61984

43
h-index

20961

115
g-index

130
all docs

130
docs citations

130
times ranked

13406
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	1.4	6
2	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	1.4	15
3	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	7.0	22
4	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2138-2147.	1.6	40
5	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
6	Socioeconomic Status and Interest in Genetic Testing in a US-Based Sample. <i>Healthcare (Switzerland)</i> , 2022, 10, 880.	2.0	7
7	SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4179-TPS4179.	1.6	2
8	Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5553-5553.	1.6	5
9	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
10	Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 691-703.	4.1	18
11	Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care. <i>Contemporary Clinical Trials</i> , 2021, 101, 106257.	1.8	5
12	Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7-7.	1.6	5
13	Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1929-1955.	3.6	9
14	Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2021, 160, 786-792.	1.4	17
15	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006083.	1.2	5
16	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	12.8	116
17	A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2602-2602.	1.6	4
18	Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8563-8563.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	2.5	7
20	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
21	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	3.1	20
22	PolyG-DS: An ultrasensitive polyguanine tractâ€‘profiling method to detect clonal expansions and trace cell lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2023373118.	7.1	0
23	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021, 36, 109412.	6.4	60
24	Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.9	42
25	Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. <i>Gynecologic Oncology</i> , 2021, 163, 130-133.	1.4	5
26	PARP inhibitor maintenance for primary ovarian cancer â€‘ A missed opportunity for precision medicine. <i>Gynecologic Oncology</i> , 2021, 163, 11-13.	1.4	7
27	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
28	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinumâ€‘based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	2.8	4
29	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	1.4	20
30	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	7.1	44
31	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	3.7	19
32	Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 602-613.	4.1	20
33	Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz076.	2.9	0
34	Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. <i>Gynecologic Oncology</i> , 2020, 156, 517-522.	1.4	16
35	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 407-414.	1.4	10
36	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	6.3	32

#	ARTICLE	IF	CITATIONS
37	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. <i>EBioMedicine</i> , 2020, 60, 102988.	6.1	27
38	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	1.4	14
39	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
40	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. <i>PLoS ONE</i> , 2020, 15, e0234505.	2.5	25
41	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 1459.	12.8	176
42	Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer. <i>Cancer Research</i> , 2020, 80, 857-867.	0.9	33
43	Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. <i>Familial Cancer</i> , 2020, 19, 143-151.	1.9	4
44	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	10.7	70
45	Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. <i>Gynecologic Oncology</i> , 2020, 157, 514-520.	1.4	18
46	Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. <i>Gynecologic Oncology</i> , 2020, 159, 214-220.	1.4	2
47	Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i> -associated breast cancer (SWOG S1416).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1001-1001.	1.6	40
48	Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1077-1077.	1.6	5
49	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1506-1506.	1.6	13
50	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6003-6003.	1.6	42
51	Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9065-9065.	1.6	6
52	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
53	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
54	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0

#	ARTICLE	IF	CITATIONS
55	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
56	Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecologic Oncology Reports, 2019, 29, 113-117.	0.6	13
57	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.	27.0	627
58	Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecologic Oncology, 2019, 153, 192-200.	1.4	80
59	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	1.4	56
60	Ovarian carcinomas express HE4 epitopes independently of each other. Cancer Treatment and Research Communications, 2019, 21, 100152.	1.7	6
61	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncology, 2019, 5, 1141.	7.1	355
62	A case of metastatic dysgerminoma treated with two cycles neoadjuvant chemotherapy followed by fertility-sparing minimally invasive surgery. Gynecologic Oncology Reports, 2019, 28, 124-127.	0.6	0
63	Olaparib and \pm -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.7	191
64	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecologic Oncology, 2019, 153, 217-222.	1.4	38
65	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature Communications, 2019, 10, 5661.	12.8	45
66	Characterization of splice-altering mutations in inherited predisposition to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26798-26807.	7.1	34
67	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	9.4	278
68	Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.. Journal of Clinical Oncology, 2019, 37, 4014-4014.	1.6	29
69	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	6.4	60
70	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncology, The, 2018, 19, 207-215.	10.7	167
71	Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecologic Oncology, 2018, 148, 281-285.	1.4	52
72	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	7.0	171

#	ARTICLE	IF	CITATIONS
73	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	12.8	192
74	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. <i>Cancer Discovery</i> , 2018, 8, 1404-1421.	9.4	311
75	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. <i>Nature Communications</i> , 2018, 9, 1849.	12.8	310
76	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5519-5519.	1.6	11
77	53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5538-5538.	1.6	0
78	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 9-20.	4.9	408
79	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 75-87.	10.7	975
80	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	9.4	310
81	Doubling Down on BRCA -Mutated Cancer. <i>Trends in Cancer</i> , 2017, 3, 743-744.	7.4	2
82	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	1.4	222
83	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 1949-1961.	13.7	1,261
84	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	1.6	209
85	Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4147-TPS4147.	1.6	2
86	Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 79175-79187.	1.8	32
87	Culprit or Bystander? The Role of the Fallopian Tube in "Ovarian" High-Grade Serous Carcinoma. <i>Cancer Discovery</i> , 2016, 6, 1309-1311.	9.4	2
88	Small cell ovarian carcinoma: Long term survival in juvenile case with poor prognostic features. <i>Gynecologic Oncology Reports</i> , 2016, 18, 45-48.	0.6	2
89	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 3894-3902.	7.0	23
90	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic <i>TP53</i> mutations in noncancerous tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6005-6010.	7.1	135

#	ARTICLE	IF	CITATIONS
91	The BRCA1- Δ 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.9	208
92	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 5651-5660.	7.0	116
93	Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 389-392.	1.4	3
94	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 379-388.	1.4	57
95	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	1.5	7
96	Somatic Mosaic Mutations in <i>PPM1D</i> and <i>TP53</i> in the Blood of Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 370.	7.1	88
97	Inherited Mutations in Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 482.	7.1	576
98	Genetic characterization of early onset ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 140, 221-225.	1.4	17
99	RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. <i>Journal of Clinical Investigation</i> , 2016, 126, 3145-3157.	8.2	74
100	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5540-5540.	1.6	25
101	Reflex test reminders in required cancer synoptic templates decrease order entry error: An analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome. <i>Journal of Pathology Informatics</i> , 2016, 7, 48.	1.7	6
102	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. <i>Gynecologic Oncology</i> , 2015, 137, 430-435.	1.4	32
103	Premalignant alterations in breast and endometrium associated with a PTEN mutation in a woman with Cowden syndrome: implications for preventive care. <i>Gynecologic Oncology Reports</i> , 2015, 12, 13-16.	0.6	3
104	DNA Repair Mutations and Outcomes in Ovarian Cancer Response. <i>Clinical Cancer Research</i> , 2015, 21, 659-659.	7.0	2
105	<i>TP53</i> mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. <i>Nucleic Acids Research</i> , 2015, 43, 6945-6958.	14.5	46
106	Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1397-1406.	1.6	295
107	Usefulness of Multigene Testing. <i>JAMA Oncology</i> , 2015, 1, 951.	7.1	20
108	More genes, more problems? Benefits and risks of multiplex genetic testing. <i>Gynecologic Oncology</i> , 2015, 139, 209-210.	1.4	9

#	ARTICLE	IF	CITATIONS
109	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. Journal of Clinical Oncology, 2015, 33, 5508-5508.	1.6	60
110	Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.. Journal of Clinical Oncology, 2015, 33, 5526-5526.	1.6	2
111	Targeting the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts: Microtubule polymerisation inhibitors.. Journal of Clinical Oncology, 2015, 33, e22202-e22202.	1.6	1
112	Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy.. Journal of Clinical Oncology, 2015, 33, 5539-5539.	1.6	0
113	The use of patient-derived xenograft models for prioritizing therapeutic targets.. Journal of Clinical Oncology, 2015, 33, 5579-5579.	1.6	0
114	Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Clinical Cancer Research, 2014, 20, 764-775.	7.0	803
115	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular Oncology, 2014, 8, 656-668.	4.6	117
116	Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.. Journal of Clinical Oncology, 2014, 32, 2569-2569.	1.6	11
117	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. Journal of Clinical Oncology, 2014, 32, TPS5619-TPS5619.	1.6	8
118	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17041-17046.	7.1	225
119	BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer, 2013, 119, 332-338.	4.1	99
120	Targeting therapy based on preclinical analysis of clinical, molecular, and functional characteristics of individual high-grade serous ovarian cancers.. Journal of Clinical Oncology, 2012, 30, 5073-5073.	1.6	0
121	Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. Journal of Clinical Oncology, 2011, 29, 3008-3015.	1.6	513
122	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18032-18037.	7.1	814
123	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12629-12633.	7.1	426
124	Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Molecular Cancer, 2009, 8, 48.	19.2	89
125	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008, 451, 1116-1120.	27.8	934
126	Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance. Cancer Research, 2008, 68, 2581-2586.	0.9	435

#	ARTICLE	IF	CITATIONS
127	Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2005, 193, 662-667.	1.3	105
128	Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. Current Treatment Options in Oncology, 2003, 4, 105-110.	3.0	3
129	Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Current Women's Health Reports, 2003, 3, 27-32.	0.2	4